✨ Free AI Report
Indivior PLC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Indivior PLC
Company Research

Indivior PLC: Business Overview, Financials & Competitive Analysis

Indivior PLC scores 7/10 on the AskCyborg Cyborg Score (Solid). Indivior is leveraging operational efficiency and SUBLOCADE momentum to drive profitable growth in the high-value OUD treatment market. The company expects to grow SUBLOCADE net revenue by 11% while growing adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points in 2026. Recent strategic execution, operational efficiency gains.

What is Indivior PLC's industry? Indivior PLC (indivior.com) operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment. AskCyborg classifies Indivior PLC under Specialty Pharmaceuticals - Opioid Use Disorder Treatment in its company registry.

Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company i...

7/ 10Solid

Cyborg Score thesis

Indivior is leveraging operational efficiency and SUBLOCADE momentum to drive profitable growth in the high-value OUD treatment...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals - Opioid Use Disorder Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Indivior PLC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Indivior PLC

AskCyborg analysts argue the bull and bear cases for Indivior PLC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Indivior PLC OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Indivior PLC Overview

Pro stress-test →

Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company is executing a strategic transformation to accelerate growth and profitability in 2026 through its Indivior Action Agenda.

Strategic Profile

Pro stress-test →

The company completed Phase I of its transformation by growing U.S. SUBLOCADE net revenue, simplifying the organization and achieving expected annual non-GAAP operating expense savings of at least $150 million. Phase II, launched January 1, 2026, focuses on accelerating U.S. SUBLOCADE dispense unit growth and net revenue while immediately accelerating adjusted EBITDA and cash flow.

Competitive Landscape

Pro stress-test →

Indivior operates in the OUD treatment pharmaceutical market competing against major pharma players offering buprenorphine and methadone formulations. Key competitors include Purdue Pharma (suboxone alternatives), Hikma Pharmaceuticals (generic buprenorphine), and emerging players in medication-assisted treatment (MAT). Indivior's SUBLOCADE (extended-release buprenorphine injection) differentiates through its once-monthly dosing convenience and clinical profile.

Industry Context

Indivior PLC operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment.

Key facts

Headquarters: Richmond, Virginia, United States · Revenue: $1.125-1.195B (2026 guidance)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Indivior PLC.

  • Shifted domicile from UK to US effective January 26, 2026, signaling strategic realignment and potential tax/operational benefits
  • Achieved S&P SmallCap 600 inclusion (December 2025), expanding institutional investor accessibility
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Announced 2026 guidance with 11% SUBLOCADE growth and 35% EBITDA growth expectations
  • January 2026Completed domicile change from UK to US parent company structure
  • +2 moreTrack every material event for Indivior PLC as it happens. Explore monitoring →
Get alerted when Indivior PLC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SuboxoneBuprenorphine-naloxone combination for OUD treatment→MethadoneSynthetic opioid agonist for opioid dependence maintenance→Generic BuprenorphineCost-effective buprenorphine formulations→

Compare Indivior PLC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Indivior PLC operates in Specialty Pharmaceuticals - Opioid Use Disorder Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Pharmaceuticals - Opioid Use Disorder Treatment research →
NEW · MCP server

Ask your AI assistant about Indivior PLC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Indivior PLC and its top competitor on Cyborg Score”
“What did Indivior PLC do this quarter?”
“Is Indivior PLC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Indivior PLC do?+
Indivior is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company i...
What is Indivior PLC's Cyborg Score?+
Indivior PLC has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Indivior PLC's main competitors?+
Named competitors include Suboxone, Methadone, Generic Buprenorphine. The full competitive landscape is in the AskCyborg report.
How can I get the full Indivior PLC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Indivior PLC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Indivior PLC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.